10:35 AM EDT, 10/03/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) and Ultima Genomics said Thursday that they are collaborating to explore Ultima's UG 100 sequencing platform and ppmSeq technology, aiming to enhance Myriad's clinical testing capabilities.

Myriad has acquired a UG 100, which will be part of its new Lab of the Future in South San Francisco. Myriad aims to improve the performance and cost of its Molecular Residual Disease test using ppmSeq on the UG 100, the companies said.

It also plans to launch the FirstGene Multiple Prenatal Screen, which will conduct multiple prenatal tests in a single sequencing process, benefiting from the UG 100, according to the companies.

Shares of Myriad Genetics ( MYGN ) fell nearly 2% in recent trading.

Price: 26.53, Change: -0.43, Percent Change: -1.59